Hospital
Mercy Hospital Fort Smith
Mercy Hospital Fort Smith was paid $22.48M by Medicaid between Jan 2018 and Dec 2024, across 397 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 4.6% of everything it billed.
33Billing provider infoMERCY HOSPITAL FORT SMITH
FORT SMITH, AR 72903
FORT SMITH, AR 72903
33aNPI1568433480assigned 01/30/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$22.48M
24GClaims1,048,252
24DCodes billed397
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arkansas
Rank by total paid#3 of 49
Median peer was paid$2.62M
This provider vs. median8.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WILCHER, GRETA controls 14+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 168,806 | $2.80M | |
| 2019 | 186,691 | $3.34M | |
| 2020 | 162,227 | $3.19M | |
| 2021 | 138,371 | $3.30M | |
| 2022 | 121,026 | $3.24M | |
| 2023 | 144,810 | $3.71M | |
| 2024incomplete | 126,321 | $2.89M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.6% | 29,178 | 8,886 | $1.03M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 6,937 | 6,453 | $854K |
| D9999 | Unspecified adjunctive procedure, by report | 3.5% | 825 | 825 | $798K |
| 80053 | Comprehensive metabolic panel | 3.4% | 54,469 | 45,316 | $775K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.2% | 9,925 | 6,939 | $718K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 7,554 | 7,001 | $676K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 2.9% | 1,935 | 1,795 | $649K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 2.6% | 2,366 | 2,184 | $575K |
| 62323 | 2.4% | 3,510 | 3,395 | $532K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.3% | 8,675 | 6,716 | $511K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 75,221 | 59,129 | $497K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.1% | 7,907 | 6,777 | $472K |
385 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.1% | 6,852 | $463K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.0% | 4,152 | $442K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.8% | 1,549 | $413K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.7% | 3,656 | $391K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.5% | 7,380 | $326K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.4% | 2,943 | $315K |
| 36415 | Collection of venous blood by venipuncture | 1.4% | 30,476 | $312K |
| 99283 | Emergency room visit (moderate) | 1.3% | 3,863 | $294K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 1,912 | $290K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.3% | 725 | $285K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.2% | 865 | $278K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 22,207 | $272K |
| 99284 | Emergency room visit (serious) | 1.2% | 3,977 | $270K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.1% | 2,150 | $254K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 7,172 | $248K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.1% | 5,467 | $246K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 1,429 | $241K |
| 80050 | General health panel | 1.1% | 6,125 | $241K |
| J0897 | Injection, denosumab, 1 mg | <1% | 904 | $216K |
| 72141 | <1% | 945 | $210K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,103 | $207K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,995 | $198K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,696 | $189K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,847 | $188K |
| 71045 | Radiologic examination, chest; single view | <1% | 18,352 | $155K |
| 96367 | <1% | 1,358 | $148K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 932 | $146K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,491 | $142K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,498 | $141K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,519 | $141K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 16,767 | $133K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,477 | $126K |
| 72131 | <1% | 1,080 | $120K | |
| 97162 | <1% | 1,514 | $118K | |
| 62321 | <1% | 711 | $116K | |
| 80081 | <1% | 1,302 | $114K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,607 | $113K |
| 84484 | <1% | 14,517 | $111K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,830 | $110K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 728 | $105K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 533 | $103K |
| 71250 | <1% | 1,653 | $99K | |
| 83880 | <1% | 5,218 | $98K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,591 | $95K |
| 80061 | Lipid panel | <1% | 10,724 | $93K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,559 | $93K |
| 87081 | <1% | 11,433 | $88K | |
| 87631 | <1% | 974 | $85K | |
| 93458 | <1% | 404 | $84K | |
| 59025 | Fetal non-stress test | <1% | 411 | $80K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 24,402 | $79K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 3,535 | $77K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,901 | $74K |
| 82947 | <1% | 6,334 | $73K | |
| 70498 | <1% | 561 | $73K | |
| 81025 | <1% | 8,062 | $71K | |
| 87653 | <1% | 1,598 | $71K | |
| 74018 | <1% | 3,137 | $70K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 369 | $68K |
| 86901 | <1% | 3,501 | $68K | |
| 70496 | <1% | 554 | $67K | |
| 82565 | <1% | 4,628 | $64K | |
| 81001 | <1% | 20,377 | $62K | |
| 83735 | <1% | 10,675 | $62K | |
| 83690 | <1% | 9,372 | $61K | |
| 73630 | <1% | 2,029 | $60K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,612 | $59K |
| 97161 | <1% | 1,309 | $59K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 499 | $58K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 595 | $58K |
| 77066 | Tomosynthesis, mammo | <1% | 887 | $57K |
| 97001 | <1% | 1,972 | $56K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 310 | $54K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,043 | $52K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,365 | $51K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,836 | $51K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,973 | $51K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,298 | $50K |
| 88342 | <1% | 1,516 | $48K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,103 | $48K |
| 88304 | <1% | 1,162 | $48K | |
| 93971 | <1% | 1,346 | $47K | |
| 82962 | <1% | 6,848 | $46K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 4,074 | $46K |
| 80074 | <1% | 1,024 | $44K | |
| 76536 | <1% | 1,286 | $44K | |
| 73221 | <1% | 195 | $43K | |
| 70486 | <1% | 393 | $42K | |
| 72128 | <1% | 361 | $42K | |
| 72100 | <1% | 1,619 | $41K | |
| 85610 | <1% | 14,209 | $40K | |
| 87040 | <1% | 3,424 | $40K | |
| 82077 | <1% | 2,563 | $39K | |
| 73030 | <1% | 1,518 | $39K | |
| 73560 | <1% | 1,176 | $39K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,254 | $38K |
| 85730 | <1% | 6,312 | $38K | |
| 87070 | <1% | 2,741 | $35K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 643 | $35K |
| 87077 | <1% | 4,815 | $33K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 864 | $33K |
| 82728 | <1% | 3,276 | $32K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,003 | $32K |
| 84702 | <1% | 3,362 | $32K | |
| 80143 | <1% | 1,673 | $32K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,540 | $32K |
| 83605 | <1% | 3,358 | $31K | |
| 76642 | <1% | 1,028 | $30K | |
| 87147 | <1% | 1,961 | $30K | |
| 80179 | <1% | 1,603 | $30K | |
| 97597 | <1% | 1,523 | $28K | |
| 82677 | <1% | 987 | $28K | |
| 84439 | <1% | 3,801 | $28K | |
| 76770 | <1% | 951 | $28K | |
| 76830 | Ultrasound, transvaginal | <1% | 567 | $27K |
| 81003 | <1% | 11,846 | $27K | |
| 93880 | <1% | 673 | $27K | |
| 76801 | <1% | 796 | $26K | |
| 73610 | <1% | 1,326 | $26K | |
| 82805 | <1% | 1,101 | $25K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,900 | $25K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 224 | $24K |
| 80320 | <1% | 1,753 | $24K | |
| 94729 | <1% | 1,267 | $24K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 979 | $23K |
| 36591 | <1% | 706 | $23K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,016 | $23K |
| 87186 | <1% | 4,596 | $22K | |
| 82105 | <1% | 1,236 | $22K | |
| 64493 | <1% | 112 | $22K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 643 | $21K |
| 73130 | <1% | 915 | $21K | |
| 36416 | <1% | 3,764 | $21K | |
| 88307 | <1% | 232 | $20K | |
| 87807 | <1% | 1,666 | $20K | |
| 87088 | <1% | 3,279 | $20K | |
| 82803 | <1% | 1,156 | $20K | |
| 84145 | <1% | 1,121 | $20K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,225 | $20K |
| 93017 | <1% | 1,180 | $19K | |
| 83970 | <1% | 781 | $19K | |
| 94727 | <1% | 1,289 | $19K | |
| 86336 | <1% | 1,004 | $18K | |
| 87210 | <1% | 3,305 | $17K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,447 | $17K |
| 86140 | <1% | 3,610 | $17K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 396 | $16K |
| 73562 | <1% | 555 | $16K | |
| 42830 | <1% | 56 | $15K | |
| 86850 | <1% | 3,196 | $15K | |
| 85014 | <1% | 2,686 | $15K | |
| 17250 | <1% | 143 | $14K | |
| 82607 | <1% | 1,543 | $14K | |
| 84481 | <1% | 1,152 | $14K | |
| 82330 | <1% | 1,166 | $14K | |
| 73110 | <1% | 584 | $13K | |
| 87641 | <1% | 652 | $13K | |
| 72170 | <1% | 487 | $13K | |
| J2704 | Injection, propofol, 10 mg | <1% | 21,011 | $12K |
| 86900 | <1% | 3,475 | $12K | |
| 71020 | <1% | 848 | $12K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 264 | $12K |
| 12001 | <1% | 57 | $11K | |
| 73502 | <1% | 534 | $11K | |
| 82746 | <1% | 1,081 | $11K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,371 | $11K |
| 43235 | <1% | 106 | $11K | |
| 85379 | <1% | 1,188 | $11K | |
| 87522 | Neg quan hep c or qual rna | <1% | 314 | $10K |
| 93922 | <1% | 643 | $10K | |
| 97165 | <1% | 194 | $10K | |
| 97003 | <1% | 319 | $10K | |
| 83550 | <1% | 1,879 | $10K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,295 | $10K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 14,975 | $10K |
| 80329 | <1% | 686 | $10K | |
| 70491 | <1% | 77 | $10K | |
| 85027 | <1% | 2,528 | $9K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 160 | $9K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 290 | $9K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 48 | $9K |
| 97166 | <1% | 121 | $9K | |
| 95811 | <1% | 73 | $9K | |
| 94060 | <1% | 336 | $8K | |
| 83540 | <1% | 2,152 | $8K | |
| 85018 | <1% | 2,405 | $8K | |
| 86696 | <1% | 365 | $8K | |
| 84132 | <1% | 1,689 | $8K | |
| 86803 | <1% | 558 | $8K | |
| 82950 | <1% | 1,386 | $8K | |
| 72040 | <1% | 292 | $8K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,062 | $8K |
| 85652 | <1% | 3,399 | $8K | |
| C1769 | Guide wire | <1% | 160 | $8K |
| 99152 | <1% | 348 | $8K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,333 | $7K |
| 43450 | <1% | 206 | $7K | |
| 82570 | <1% | 2,366 | $7K | |
| 84703 | <1% | 774 | $7K | |
| 87205 | <1% | 2,105 | $7K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 94 | $7K |
| 90715 | <1% | 461 | $6K | |
| 84112 | <1% | 88 | $6K | |
| 84295 | <1% | 1,303 | $6K | |
| 86592 | <1% | 1,341 | $6K | |
| 82550 | <1% | 1,009 | $6K | |
| 80076 | <1% | 930 | $6K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 7,917 | $6K |
| 84153 | <1% | 411 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,760 | $5K |
| 82248 | <1% | 925 | $5K | |
| 82043 | <1% | 1,654 | $5K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,977 | $5K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 638 | $5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 142 | $5K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 930 | $5K |
| 96417 | <1% | 54 | $5K | |
| 82010 | <1% | 691 | $5K | |
| 80069 | <1% | 877 | $5K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 29 | $5K |
| 87634 | <1% | 54 | $5K | |
| 71010 | <1% | 600 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,794 | $4K |
| 77334 | <1% | 37 | $4K | |
| 93970 | <1% | 166 | $4K | |
| 81002 | <1% | 1,228 | $4K | |
| 82247 | <1% | 596 | $4K | |
| 86039 | <1% | 467 | $4K | |
| 86695 | <1% | 364 | $4K | |
| 77065 | Tomosynthesis, mammo | <1% | 96 | $4K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,427 | $4K |
| 84480 | <1% | 345 | $3K | |
| 83615 | <1% | 803 | $3K | |
| 80164 | <1% | 364 | $3K | |
| 86038 | <1% | 348 | $3K | |
| 84550 | <1% | 1,001 | $3K | |
| 77412 | <1% | 123 | $3K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 80 | $3K |
| 84146 | <1% | 130 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,601 | $3K |
| 12011 | <1% | 15 | $3K | |
| 80047 | <1% | 43 | $3K | |
| 74000 | <1% | 157 | $3K | |
| 73590 | <1% | 100 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,184 | $3K |
| 36600 | <1% | 219 | $3K | |
| 87340 | <1% | 243 | $2K | |
| 12002 | <1% | 15 | $2K | |
| 87428 | <1% | 37 | $2K | |
| 84156 | <1% | 865 | $2K | |
| 82784 | <1% | 140 | $2K | |
| 87899 | <1% | 270 | $2K | |
| 78306 | <1% | 28 | $2K | |
| 36430 | <1% | 25 | $2K | |
| 73070 | <1% | 135 | $2K | |
| 88341 | <1% | 14 | $2K | |
| A9270 | Non-covered item or service | <1% | 5,790 | $2K |
| 87493 | <1% | 81 | $2K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 124 | $2K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 436 | $2K |
| 86431 | <1% | 385 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,520 | $2K |
| 93226 | <1% | 44 | $2K | |
| 81000 | <1% | 489 | $2K | |
| 84403 | <1% | 72 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 258 | $2K |
| 84100 | <1% | 381 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,061 | $2K |
| 83655 | <1% | 93 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 31 | $2K |
| 77336 | <1% | 57 | $1K | |
| 82140 | <1% | 298 | $1K | |
| 87075 | <1% | 133 | $1K | |
| 97164 | <1% | 46 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,752 | $1K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,566 | $1K |
| 77080 | <1% | 16 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,405 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,439 | $1K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,583 | $1K |
| 73090 | <1% | 68 | $1K | |
| 74022 | <1% | 49 | $987.34 | |
| 87400 | <1% | 81 | $964.50 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 3,864 | $928.71 |
| 82951 | <1% | 81 | $918.92 | |
| 94010 | <1% | 77 | $904.82 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,859 | $892.41 |
| 86300 | <1% | 68 | $879.15 | |
| 96415 | <1% | 16 | $868.30 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,136 | $862.13 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 45 | $836.48 |
| 80177 | <1% | 117 | $834.77 | |
| 85045 | <1% | 293 | $767.46 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 221 | $744.41 |
| 88142 | <1% | 48 | $699.33 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 3,156 | $664.57 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 274 | $660.13 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,859 | $655.37 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,680 | $648.42 |
| 87045 | <1% | 72 | $628.51 | |
| 90686 | <1% | 99 | $548.76 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 825 | $541.52 |
| 87328 | <1% | 56 | $534.61 | |
| 87329 | <1% | 56 | $523.78 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 654 | $518.15 |
| 87046 | <1% | 72 | $500.62 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 2,070 | $491.37 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,190 | $463.73 |
| 82150 | <1% | 80 | $451.54 | |
| 29580 | <1% | 39 | $450.85 | |
| 86762 | <1% | 24 | $431.55 | |
| 92523 | <1% | 13 | $385.52 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 210 | $377.90 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 26 | $370.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 40 | $355.00 |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | <1% | 1,488 | $350.36 |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,551 | $316.41 |
| 97116 | <1% | 360 | $314.21 | |
| 76870 | <1% | 12 | $304.52 | |
| 80349 | <1% | 16 | $298.90 | |
| 83001 | <1% | 13 | $292.05 | |
| 82952 | <1% | 81 | $287.11 | |
| 83516 | <1% | 16 | $253.85 | |
| 83930 | <1% | 30 | $227.00 | |
| 86200 | <1% | 29 | $225.12 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 14 | $219.00 |
| 99153 | Mod sedat endo service >5yrs | <1% | 86 | $218.21 |
| 84165 | <1% | 27 | $204.47 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 28 | $185.98 |
| 86923 | <1% | 46 | $183.60 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 97 | $166.92 |
| 0353U | <1% | 238 | $164.94 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 372 | $164.50 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 265 | $150.40 |
| G0378 | Hospital observation service, per hour | <1% | 442 | $144.96 |
| 88312 | <1% | 62 | $143.00 | |
| 93923 | <1% | 17 | $141.30 | |
| 83921 | <1% | 14 | $141.06 | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 112 | $135.60 |
| 83986 | <1% | 29 | $128.00 | |
| 82378 | <1% | 13 | $108.36 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 206 | $81.60 |
| 80178 | <1% | 13 | $66.01 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 440 | $65.64 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 165 | $59.89 |
| 83883 | <1% | 14 | $58.26 | |
| 84460 | <1% | 13 | $45.36 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 376 | $34.99 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 178 | $33.40 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 21 | $27.84 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 12 | $27.40 |
| 82340 | <1% | 12 | $25.86 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 206 | $24.85 |
| 96376 | <1% | 2,381 | $22.44 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 99 | $16.61 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 19 | $15.91 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 70 | $15.52 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 62 | $14.64 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 2,339 | $13.56 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 232 | $10.68 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 38 | $7.61 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 405 | $5.93 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 228 | $5.36 |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 13 | $4.83 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 42 | $3.27 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 283 | $3.20 |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 56 | $2.61 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 391 | $1.80 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 283 | $1.10 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 257 | $0.96 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | <1% | 83 | $0.14 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 673 | $0.02 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 390 | $0.01 |
| G0008 | Administration of influenza virus vaccine | 0% | 57 | $0.00 |
| 97010 | 0% | 156 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 1,283 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 817 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 77 | $0.00 |
| 94761 | 0% | 12 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 18 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 189 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 26 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 47 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 50 | $0.00 |
| 92610 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILCHER, GRETA (CFO)
| Provider | Location | Paid |
|---|---|---|
| Mercy Clinic Fort Smith Communities | Fort Smith, AR | $24.10M |
| Mercy Hospital Rogers | Rogers, AR | $14.20M |
| Mercy Health Northwest Arkansas Communities | Rogers, AR | $8.38M |
| Mercy Clinic Fort Smith Communities | Fort Smith, AR | $2.28M |
| Mercy Hospital Rogers | Rogers, AR | $1.83M |
| Mercy Clinic Fort Smith Communities | Fort Smith, AR | $1.62M |
| Mercy Health Northwest Arkansas Communities | Rogers, AR | $318K |
| Mercy Hospital Fort Smith | Fort Smith, AR | $298K |
| Mercy Health Northwest Arkansas Communities | Rogers, AR | $207K |
| Mercy Health Northwest Arkansas Communities | Rogers, AR | $104K |
| Mercy Health Northwest Arkansas Communities | Bella Vista, AR | $86K |
| ST Edward Mercy Foundation | Fort Smith, AR | $74K |
| Mercy Health Northwest Arkansas Communities | Rogers, AR | $26K |
| Mercy Hospital Fort Smith | Fort Smith, AR | $127.47 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.